title: [Severe Wegener's granulomatosis successfully treated with rituximab].
abstract: The paper discusses the problems of the diagnosis and treatment of Wegener's granulomatosis, the most common anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. It describes a clinical case in which the administration of rituximab could achieve remission of severe Wegener's granulomatosis in a young man having numerous adverse reactions associated with the long-term use of high- and average-dose glucocorticoids and nonselective immunosuppressive agents. A place of rituximab in current drug therapy for Wegener's granulomatosis is shown.
authors: E N
authors: EN
authors: Semenkova
authors: O G
authors: OG
authors: Krivosheev
authors: P I
authors: PI
authors: Novikov
authors: V I
authors: VI
authors: Osipenko
authors: N R
authors: NR
authors: Nosova
authors: S A
authors: SA
authors: Parfenova
authors: N V
authors: NV
authors: Nikiforova
authors: O O
authors: OO
authors: Borodin
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use*; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D000069283:Rituximab; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab